Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of BILR 355 BS with Ritonavir in Healthy Volunteers
NCT02253953Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2002
- Primary completion
- Dec 2003
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of BILR 355 in human immunodeficiency virus type 1 infection (HIV-1) (10 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum observed concentration of the analyte in plasma up to 120 hours, Time to reach Cmax up to 120 hours and 7 more. Started Nov 2002; status: completed.
02
Drugs
BILR 355
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02253953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02253953.